醋酸戈舍瑞林缓释植入剂结合比卡鲁胺片治疗高龄前列腺癌(PCA)患者的临床效果分析

Clinical Effect of Goserelin Acetate Sustained-release Implant Combined with Bikarramine Tablets on Elderly Patients with Prostate Cancer(PCA)

目的:探讨醋酸戈舍瑞林缓释植入剂结合比卡鲁胺片治疗高龄前列腺癌(PCA)患者的临床应用效果。方法:选取62例PCA患者随机分为对照组和研究组各31例,对照组予以去势治疗,研究组予以醋酸戈舍瑞林缓释植入剂结合比卡鲁胺片治疗,比较两组患者临床疗效,血清α-甲酰基辅酶A消旋酶(P504S)、前列腺特异抗原(PSA)水平以及治疗后1年生存情况。结果:研究组患者临床总有效率(83.87%)较对照组(58.06%)明显要高(P<0.05);两组患者干预前血清P504S、PSA水平比较无显著性差异(P>0.05),干预后两组比较有差异,且与干预前比较有差异(P<0.05);研究组1年后生存率(90.32%)较对照组(61.29%)明显要高(P<0.05)。结论:高龄PCA患者采用醋酸戈舍瑞林缓释植入剂结合比卡鲁胺片治疗可显著降低血清P504S、PSA水平,提高生存率。

Objective:To investigate the clinical effect of goserelin acetate sustained-release implant combined with bikarramine tablet in the treatment of elderly patients with prostate cancer(PCA).Methods:62 PCA patients were randomly divided into 2 groups,31 cases in the control group were treated with castration,31 cases in the study group were treated with goserelin acetate sustained-release implant combined with bikarramine tablets,then the clinical efficacy,serumα-formyl-coenzyme A racemase(P504S),prostate-specific antigen(PSA)levels,and survival after 1 year of treatment were compared between the two groups.Results:The total clinical effective rate in the study group(83.87%)was higher than that in the control group(58.06%)(P<0.05).There was no significant difference in serum P504S and PSA levels between the two groups before intervention(P>0.05).After intervention,there was difference between the two groups,and both groups had difference after intervention compared with before intervention(P<0.05).Survival rate after 1 year in the study group(90.32%)was significantly higher than that in the control group(61.29%)(P<0.05).Conclusion:Goserelin acetate sustained-release implant combined with bikarramine tablet can significantly reduce serum P504S,PSA levels and improve survival rate in elderly PCA patients.